PRINCETON, N.J. / Dec 20, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference in New York City on Thursday, January 4, 2024. Adam Lenkowsky, executive vice president, chief commercialization officer, will answer questions about the company during a fireside chat at 11 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$48.44 |
| Daily Change: | 0.63 1.32 |
| Daily Volume: | 10,619,768 |
| Market Cap: | US$98.820B |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
